Free Trial

27,063 Shares in LivaNova PLC (NASDAQ:LIVN) Acquired by Y Intercept Hong Kong Ltd

LivaNova logo with Medical background

Y Intercept Hong Kong Ltd purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,063 shares of the company's stock, valued at approximately $1,063,000.

Several other hedge funds have also recently modified their holdings of the stock. Allianz Asset Management GmbH acquired a new position in shares of LivaNova during the 1st quarter worth about $593,000. Foundry Partners LLC purchased a new stake in LivaNova during the 1st quarter valued at about $3,816,000. CWM LLC grew its stake in LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after acquiring an additional 299 shares in the last quarter. New York State Common Retirement Fund grew its stake in LivaNova by 28.6% during the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock valued at $1,897,000 after acquiring an additional 10,733 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in LivaNova by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock valued at $817,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Trading Up 0.0%

Shares of LivaNova stock traded up $0.01 during mid-day trading on Monday, hitting $43.68. The stock had a trading volume of 165,310 shares, compared to its average volume of 687,942. The firm has a 50-day moving average of $44.69 and a two-hundred day moving average of $42.98. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $57.35. The company has a quick ratio of 1.37, a current ratio of 1.58 and a debt-to-equity ratio of 0.53. The firm has a market cap of $2.38 billion, a P/E ratio of -10.70 and a beta of 0.90.

Analysts Set New Price Targets

Several analysts recently issued reports on LIVN shares. Barclays dropped their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Robert W. Baird upped their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of "Buy" and an average target price of $59.29.

Read Our Latest Stock Analysis on LIVN

LivaNova Profile

(Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Articles

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Should You Invest $1,000 in LivaNova Right Now?

Before you consider LivaNova, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.

While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines